Everolimus: side effect profile and management of toxicities in breast cancer

  title={Everolimus: side effect profile and management of toxicities in breast cancer},
  author={Elisavet Paplomata and Amelia B. Zelnak and Ruth M. O’Regan},
  journal={Breast Cancer Research and Treatment},
Everolimus is an orally available inhibitor of the mammalian target of rapamycin (mTOR), which has been approved in combination with exemestane for hormone receptor-positive (HR) breast cancer after failure of treatment with non-steroidal aromatase inhibitors. Everolimus is generally very well tolerated with most common side effects including stomatitis, rash, fatigue, hyperglycemia, hyperlipidemia, and myelosuppression. Most of these side effects are mild and resolve with dose interruptions or… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 24 extracted citations

mTORC1/2 inhibition preserves ovarian function and fertility during genotoxic chemotherapy.

Proceedings of the National Academy of Sciences of the United States of America • 2017
View 1 Excerpt


Publications referenced by this paper.
Showing 1-10 of 46 references

A review of oral toxicity associated with mTOR inhibitor therapy in cancer patients

F Martins, MA de Oliveira, +4 authors N Treister
Oral Oncol 49(4):293–298 • 2013
View 1 Excerpt

Cancer statistics , 2013

R Siegel, D Naishadham
CA Cancer J Clin • 2013

Hematology : basic principles and practice, 6th edn

R Hoffman
View 1 Excerpt

Similar Papers

Loading similar papers…